ëïãüôõðï ÃÃÅÔ

 

 

 

 

 

FP6 TOK-IAP (MTKI 029640-2005) “Biomarker Discovery” (2006-2008)

FP7 ERG 202132 “Advanced Bioanalytical Technologies for systems biology Studies” (2008-2011)

Metabonomic/Metabolomic Research

This is the major research line of the group.

Along the realisation of a Transfer of Knowledge Industry Academia Partnership with AstraZeneca UK (Department of Drug Metabolism and Pharmacokinetics Alderley Park) and a European Reintegration Grant (Dr. H. Gika) the core of the bioanalysis group research is focused on global metabolite profiling using hyphenated techniques (LC-MS, GC-MS) and NMR.

We now run EmryoMetabolomics (GSRT, 2012-2015) and two Irakleitos grants (GSRT,  2010-2013) on arthritis and drug toxicity assessment.

The major scope of our research lays on the discovery of biomarkers of disease onset (diagnosis) and progression (prognostic markers), drug efficacy and drug toxicity.

back